PCSK9 inhibition with alirocumab has been shown to strongly lower LDL-C and non-HDL-C alone and on top of statin, and reduce the risk of recurrent ischemic cardiovascular events in patients with acute coronary syndrome (28). This evidence concerns the gene PCSK9 and acute coronary syndrome.